Provectus Biopharmaceuticals, Inc.
PVCT
$0.05
$0.00-0.75%
OTC PK
| 06/30/2026 | 03/31/2026 | 12/31/2025 | 09/30/2025 | 06/30/2025 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -100.00% | -- | -77.45% |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -100.00% | -- | -77.45% |
| Cost of Revenue | -87.41% | -18.33% | -54.60% | -20.28% | 88.77% |
| Gross Profit | 86.51% | -204.80% | 53.38% | -9.34% | -300.70% |
| SG&A Expenses | -14.33% | -5.95% | -54.84% | 80.56% | 91.74% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | -50.44% | -9.35% | -55.20% | 34.92% | 91.74% |
| Operating Income | 48.73% | -13.66% | 54.92% | -54.50% | -158.22% |
| Income Before Tax | 46.62% | -11.99% | 51.28% | -30.48% | -118.72% |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | 46.62% | -11.99% | 51.28% | -30.48% | -118.72% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -83.55% | -51.16% | -90.54% | -- | -- |
| Net Income | 45.84% | -13.19% | 50.79% | -29.27% | -114.27% |
| EBIT | 48.73% | -13.66% | 54.92% | -54.50% | -158.22% |
| EBITDA | 48.75% | -13.66% | 54.93% | -54.90% | -159.02% |
| EPS Basic | 46.51% | -14.81% | 50.00% | -29.17% | -115.00% |
| Normalized Basic EPS | 48.00% | -11.76% | 52.94% | -50.00% | -127.27% |
| EPS Diluted | 46.51% | -14.81% | 50.00% | -29.17% | -115.00% |
| Normalized Diluted EPS | 48.00% | -11.76% | 52.94% | -50.00% | -127.27% |
| Average Basic Shares Outstanding | 0.00% | 0.00% | 0.00% | 0.09% | 0.18% |
| Average Diluted Shares Outstanding | 0.00% | 0.00% | 0.00% | 0.09% | 0.18% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |